$LQDA

Bloch Stephen M sold $7.6M of LQDA (indirect holdings)

Bloch Stephen M sold 100,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $75.74 ($75.54–$76.18, $7.57M total) across 2 trades on 2026-06-22.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed open-market sale provides a fresh, filing-based datapoint on insider behavior, but it does not include new guidance, trial results, or regulatory outcomes.

02

Market read

Traders may briefly reassess sentiment around LQDA based on the size of the director sale, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamentals.

03

What to watch

The transaction is described as indirect holdings and does not clarify tax/estate mechanics; traders should watch for subsequent filings (additional sales/buys) and any concurrent company news.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA) by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 100,000 shares in open-market transactions on 2026-06-22 for about $7.57M total value.

Expected impact

Likely limited, short-lived impact unless follow-on selling or new company fundamentals emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with disclosed sale size and price range, but it provides no new operational/financial information; also notes no 10b5-1 plan.

Market effects

Minimal; this is company-specific insider selling with no sector-wide regulatory/earnings signal.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events; without a 10b5-1 plan, the sale still may reflect pre-existing personal needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure (LQDA).

  • Stephen M. Bloch

    Director who sold 100,000 shares in open-market transactions on 2026-06-22; indirect holdings; no 10b5-1 plan stated.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.